After 12 weeks of HFD administration, the serum activities of ALT and AST were significantly higher (1.78‐fold and 4.06‐fold, respectively) in the NAFLD group than in the control group (p = 0.0007 and < 0.0001, respectively; Figure 2). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.